239 related articles for article (PubMed ID: 31690656)
21. Nuclear membrane ruptures underlie the vascular pathology in a mouse model of Hutchinson-Gilford progeria syndrome.
Kim PH; Chen NY; Heizer PJ; Tu Y; Weston TA; Fong JL; Gill NK; Rowat AC; Young SG; Fong LG
JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423791
[TBL] [Abstract][Full Text] [Related]
22. Next-Generation Sequencing and Quantitative Proteomics of Hutchinson-Gilford progeria syndrome-derived cells point to a role of nucleotide metabolism in premature aging.
Mateos J; Fafián-Labora J; Morente-López M; Lesende-Rodriguez I; Monserrat L; Ódena MA; Oliveira E; de Toro J; Arufe MC
PLoS One; 2018; 13(10):e0205878. PubMed ID: 30379953
[TBL] [Abstract][Full Text] [Related]
23. Vascular calcification is dependent on plasma levels of pyrophosphate.
Lomashvili KA; Narisawa S; Millán JL; O'Neill WC
Kidney Int; 2014 Jun; 85(6):1351-6. PubMed ID: 24717293
[TBL] [Abstract][Full Text] [Related]
24. Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.
Sagelius H; Rosengardten Y; Schmidt E; Sonnabend C; Rozell B; Eriksson M
J Med Genet; 2008 Dec; 45(12):794-801. PubMed ID: 18708427
[TBL] [Abstract][Full Text] [Related]
25. Arterial calcification is driven by RAGE in Enpp1-/- mice.
Cecil DL; Terkeltaub RA
J Vasc Res; 2011; 48(3):227-35. PubMed ID: 21099228
[TBL] [Abstract][Full Text] [Related]
26. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
Kreienkamp R; Croke M; Neumann MA; Bedia-Diaz G; Graziano S; Dusso A; Dorsett D; Carlberg C; Gonzalo S
Oncotarget; 2016 May; 7(21):30018-31. PubMed ID: 27145372
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of arterial medial calcification and bone mineralization by extracellular nucleotides: The same functional effect mediated by different cellular mechanisms.
Patel JJ; Zhu D; Opdebeeck B; D'Haese P; Millán JL; Bourne LE; Wheeler-Jones CPD; Arnett TR; MacRae VE; Orriss IR
J Cell Physiol; 2018 Apr; 233(4):3230-3243. PubMed ID: 28976001
[TBL] [Abstract][Full Text] [Related]
28. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
Hamczyk MR; Andrés V
Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
[TBL] [Abstract][Full Text] [Related]
29. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Qiao X; Fong LG; Young SG
Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
[TBL] [Abstract][Full Text] [Related]
30. Hydrolysis of Extracellular ATP by Vascular Smooth Muscle Cells Transdifferentiated into Chondrocytes Generates P
Buchet R; Tribes C; Rouaix V; Doumèche B; Fiore M; Wu Y; Magne D; Mebarek S
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799449
[TBL] [Abstract][Full Text] [Related]
31. Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome.
Cabral WA; Tavarez UL; Beeram I; Yeritsyan D; Boku YD; Eckhaus MA; Nazarian A; Erdos MR; Collins FS
Aging Cell; 2021 Sep; 20(9):e13457. PubMed ID: 34453483
[TBL] [Abstract][Full Text] [Related]
32. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells.
Hamczyk MR; Villa-Bellosta R; Quesada V; Gonzalo P; Vidak S; Nevado RM; Andrés-Manzano MJ; Misteli T; López-Otín C; Andrés V
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30862662
[TBL] [Abstract][Full Text] [Related]
33. Hutchinson-Gilford progeria syndrome.
Ullrich NJ; Gordon LB
Handb Clin Neurol; 2015; 132():249-64. PubMed ID: 26564085
[TBL] [Abstract][Full Text] [Related]
34. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
35. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification.
Narisawa S; Harmey D; Yadav MC; O'Neill WC; Hoylaerts MF; Millán JL
J Bone Miner Res; 2007 Nov; 22(11):1700-10. PubMed ID: 17638573
[TBL] [Abstract][Full Text] [Related]
36. Arterial stiffness and cardiac dysfunction in Hutchinson-Gilford Progeria Syndrome corrected by inhibition of lysyl oxidase.
von Kleeck R; Roberts E; Castagnino P; Bruun K; Brankovic SA; Hawthorne EA; Xu T; Tobias JW; Assoian RK
Life Sci Alliance; 2021 May; 4(5):. PubMed ID: 33687998
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats.
Côté N; El Husseini D; Pépin A; Bouvet C; Gilbert LA; Audet A; Fournier D; Pibarot P; Moreau P; Mathieu P
Eur J Pharmacol; 2012 Aug; 689(1-3):139-46. PubMed ID: 22659116
[TBL] [Abstract][Full Text] [Related]
38. Progeria of stem cells: stem cell exhaustion in Hutchinson-Gilford progeria syndrome.
Halaschek-Wiener J; Brooks-Wilson A
J Gerontol A Biol Sci Med Sci; 2007 Jan; 62(1):3-8. PubMed ID: 17301031
[TBL] [Abstract][Full Text] [Related]
39. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
40. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
